Paul LePage: ABUSE-DETERRENT OPIOIDS

Portland Press Herald Editorial HEADLINE: “Our View: Maine Pain Patients Should Get Access To Less-Addictive Drugs.” [Editorial, Portland Press Herald, 5/14/15]

HEADLINE: “Maine Bill Would Help Patients Buy Opiates That Deter Addiction.” [Portland Press Herald, 5/11/15]

HEADLINE: “Maine Bill Aims To Make Abuse-Deterrent Painkillers More Affordable.” [NPR, 5/20/15]

In 2015, Bipartisan Majorities of the House and Senate Overrode LePage’s Veto of a Bill Mandating That Patients Who Were Prescribed Opioids With “Abuse-Deterrent Formulations” Were Charged the Same Co-Pay They Would Pay for Regular Opioids. In June 2015, the House voted to override LePage’s veto of LD919 by a 119-13 vote and the Senate voted 34-0 to concur in the veto override. “Co-sponsored by Democratic Reps. Barry Hobbins of Saco and Sara Gideon of Freeport and Republican Sens. Roger Katz of Augusta and Amy Volk of Scarborough, L.D. 919 would mandate that patients who are prescribed drugs with abuse-deterrent formulations pay the same co-pay as they would for painkillers that lack these properties.” 5. [Editorial, Kennebec Journal, 5/14/15; Joint Standing Committee on Insurance and Financial Services, Summaries of Bills, LD 919, August 2015; State of Maine Legislature, Actions for LD 919, 7/16/15; State of Maine Legislature, LD 919, Roll Call #457, 6/30/15]

  • Portland Press Herald: Under the Bill, “Health Insurance Companies Would Not Be Allowed To Charge Patients More For Less Addictive Versions Of Prescription Opiates.” “Health insurance companies would not be allowed to charge patients more for less addictive versions of prescription opiates under a new bill being considered in the Maine Legislature.” [Portland Press Herald, 5/11/15]
  • The Bill Would “Remove The Financial Incentive For Patients To Choose The Cheaper Versions – And Therefore Make Them Less Likely To Abuse And Become Addicted To Them.” “The bill would remove the financial incentive for patients to choose the cheaper versions – and therefore make them less likely to abuse and become addicted to them. The bill does not affect the cost of the drugs for those who would pay for them out-of-pocket, such as the uninsured.” [Portland Press Herald, 5/11/15]

Kennebec Journal Editorial: “The Less Addictive Versions Of Prescription Opiates Can Cost Hundreds Of Dollars More Per Month.” “To stem the tide of addiction, technology has been developed that prevents users from chewing, crushing, grating or grinding pain pills to experience the ‘high.’ But the less addictive versions of prescription opiates can cost hundreds of dollars more per month.” [Editorial, Kennebec Journal, 5/14/15]

Kennebec Journal Editorial: Insurers Opposed the Legislation To Charge The Same Co-Pay For Less Addictive Opioids, Saying The Abuse-Deterrent Formulations Were Often More Expensive. “If the bill is approved, it would remove the financial incentive for consumers to choose the cheaper versions, to which it's easier to become addicted. Insurers have objected to L.D. 919, claiming that because abuse-deterrent formulations are often more expensive, the bill could result in higher premiums. But this criticism overlooks the high price of addiction.” [Editorial, Kennebec Journal, 5/14/15]

Kennebec Journal Editorial: “If The Bill Is Approved, It Would Remove The Financial Incentive For Consumers To Choose The Cheaper Versions, To Which It's Easier To Become Addicted.” “If the bill is approved, it would remove the financial incentive for consumers to choose the cheaper versions, to which it's easier to become addicted.” [Editorial, Kennebec Journal, 5/14/15]

Kennebec Journal Editorial: “While Abuse-Deterrent Medications Aren’t A Silver Bullet, Making Them More Available And More Affordable Could Reduce The Risk Of Addiction. By Supporting L.D. 919, Our Elected Officials Have An Opportunity To Make This Happen.” “But while abuse-deterrent medications aren’t a silver bullet, making them more available and more affordable could reduce the risk of addiction. By supporting L.D. 919, our elected officials have an opportunity to make this happen.” [Editorial, Kennebec Journal, 5/14/15]

Portland Press Herald Editorial: “The Less Addictive Versions Of Prescription Opiates Can Cost Hundreds Of Dollars More Per Month.” “To stem the tide of addiction, technology has been developed that prevents users from chewing, crushing, grating or grinding pain pills to experience the ‘high.’ But the less addictive versions of prescription opiates can cost hundreds of dollars more per month.” [Editorial, Portland Press Herald, 5/14/15]

  • 2015: Opiate Painkiller Zohydro, Without Abuse-Deterrent Properties, Cost $15.98 Per Day, While Abuse-Deterrent OxyContin Cost $31.73 Per Day. “Although drug prices vary widely and abuse-deterrent drugs are not always more expensive, in many cases there is a difference in prices for medications depending on whether they have abuse-deterrent properties. For instance, Zohydro, an opiate painkiller not available with abuse-deterrent properties, costs $15.98 per day, while abuse-deterrent OxyContin costs $31.73 per day, on average, according to www.goodrx.com, a price comparison website.” [Portland Press Herald, 5/11/15]
  • 2016: A 30-Day Supply Of Pfizer’s Abuse-Deterrent Opioid Cost $268 While A 30-Day Supply Of Generic Morphine Cost $38. “Federal health officials also have pushed back against requirements to cover the drugs, citing the “staggering” costs. For example, a 30-day supply of Pfizer’s abuse-deterrent Embeda, a combination drug containing morphine, costs $268, while a 30-day supply of a generic morphine costs roughly $38, according to data compiled by Truven Health Analytics, a company that tracks drug prices set by manufacturers.” [CBS, 12/15/16]

Source report (PDF)